Indevr, Inc.
Boulder, CO
- UEI
- CX4ZCPH2EAA3
- CAGE
- 3G9T5
- Primary NAICS
- 334516 Analytical Laboratory Instrument Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 6035 Longbow Dr Suite 102, Boulder, CO 80301, USA
- Website
- indevr.com
- Founded
- 2003
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $133,840 |
| FY2025 | $0 |
| FY2024 | $0 |
| FY2023 | $325,645 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $133,840 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Tetracore, Inc. | Rockville, MD | 334519 Other Measuring and Controlling Device Manufacturing |
| Bio Rad Laboratories Inc. | Hercules, CA | 334516 Analytical Laboratory Instrument Manufacturing |
| Luminex Corp | Austin, TX | 325413 In-Vitro Diagnostic Substance Manufacturing |
| Biofire Diagnostics LLC | Salt Lake City, UT | 334516 Analytical Laboratory Instrument Manufacturing |
| Diasorin Molecular, LLC | Cypress, CA | 325413 In-Vitro Diagnostic Substance Manufacturing |
About the company
Indevr, Inc., a foreign-owned for-profit manufacturer of analytical laboratory instruments based in Boulder, Colorado, supplies specialized microarray systems, assay kits, and diagnostic reagents to federal health and defense agencies as a prime contractor exclusively — the vendor holds no subcontract work and competes full-and-open without set-aside designations, except for a recent Total Small Business set-aside purchase order from the FDA. The vendor's federal footprint is concentrated in vaccine characterization and therapeutic antibody development platforms, anchored by proprietary VaxArray microarray imaging systems and custom serology panels.
Indevr's customer base splits between two dominant agencies by potential value. The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response accounts for $21.5 million (two awards, 89% of total potential value), while the Department of the Army Medical Command, the National Institute of Allergy and Infectious Diseases, the Bureau of Medicine and Surgery, and the FDA collectively represent the remaining 11 percent across 23 awards. By award count, NIAID and Army Medical Command lead with seven and six awards respectively; however, the dollar concentration is dramatically asymmetric — ASPR's two awards dwarf the volume-heavy agencies. Indevr places work under a single named parent vehicle, an Army IDC (W81XWH14D0010), which carries two task orders valued at $690 thousand combined.
The vendor's concrete capability portfolio centers on multiplex microarray assay platforms for serological testing. Representative recent work includes a $240.75 thousand sole-source supply contract awarded by NIAID in August 2023 for custom serology panels of 18 antigens and detection antibodies supporting therapeutic antibody isolation projects, an $84.895 thousand sole-source contract from NIAID in August 2023 for a Multiplex Microarray Assay Imaging System (VaxArray), a $94.45 thousand sole-source Navy contract from September 2021 for VaxArray coronavirus seroassay kits and performance assessment multivalent assay kits, and the FDA's $133.84 thousand Total Small Business set-aside purchase order in April 2026 for a microarray system with analysis package. All NIAID and Navy awards prior to the April 2026 FDA order carried sole-source designations, justified by Indevr's exclusive ownership of the VaxArray intellectual property and microarray slide printing process. The vendor manufactures instruments and reagents in-house at its Boulder facility.
Activity shows volatility across the twenty-one-year source window — five awards in 2021, two in 2023, one in 2022, and one in 2026 — with combined dollars obligated ($30.7 million) exceeding combined potential value ($24.1 million) by 28 percent, indicating invoice-heavy performance on prior-year awards. Only one award reaches ultimate completion inside the next twenty-four months (the FDA purchase order, valued at $134 thousand), presenting minimal recompete exposure in that window.
Quick answers
Is Indevr, Inc. registered in SAM.gov?
Yes. Indevr, Inc.'s SAM.gov registration is active through March 10, 2027.
What is Indevr, Inc.'s CAGE code?
Indevr, Inc.'s CAGE code is 3G9T5, and its Unique Entity ID (UEI) is CX4ZCPH2EAA3.
How much has Indevr, Inc. received in federal contracts?
Federal contracts obligated $459,485 to Indevr, Inc. in fiscal years 2023 through 2027.
What is Indevr, Inc.'s most recent federal award?
Indevr, Inc.'s most recent federal contract award is Microarray system W/analysis package (75F40126P00037), from Food and Drug Administration, on April 28, 2026.
On GovTribe
See Indevr, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors